Combination therapy for treating cancer
AssigneesLeukos Biotech, S.L., Fundació Institut De Recerca Contra La LeucèMia Josep Carreras
InventorsRuth Muñoz Risueño, Mari Carmen Lara Castillo, Amaia Etxabe Alberdi
Life of this patent
Estimating the term…
Abstract
The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR1) modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.
Claims15
A synergistic combination for the treatment of a hematological malignancy comprising
- (a) an ATC/DDD L01B antimetabolite;
- and
- (b) a type 1A or type 1B HTR serotonin receptor (HTR1A or HTR1B) small molecule antagonist, at a molar ratio of HTR1A or HTR1B small molecule antagonist to ATC/DDD L01B antimetabolite between
- (i) 500:1 and 2:1 when the ATC/DDD L01B antimetabolite is a pyrimidine analogue;
- (ii) 1000:1 and 5:1 when the ATC/DDD L01B antimetabolite is a purine analogue;
- or
- (iii) 4000:1 to 400:1 when the ATC/DDD L01B antimetabolite is a folic acid analogue;
- wherein the synergistic combination comprising the ATC/DDD L01B antimetabolite and the HTR1A or HTR1B small molecule antagonist is capable of synergistically killing hematological malignancy cells expressing HTR1A or HTR1B.
A dosage form comprising a synergistic combination of
- (a) an ATC/DDD L01B antimetabolite;
- and
- (b) a type 1A or type 1B HTR serotonin receptor (HTR1A or HTR1B) small molecule antagonist, at a molar ratio of HTR1A or HTR1B small molecule antagonist to ATC/DDD L01B antimetabolite between
- (i) 500:1 and 2:1 when the ATC/DDD L01B antimetabolite is a pyrimidine analogue;
- (ii) 1000:1 and 5:1 when the ATC/DDD L01B antimetabolite is a purine analogue;
- or
- (iii) 4000:1 to 400:1 when the ATC/DDD L01B antimetabolite is a folic acid analogue;
- wherein the synergistic combination comprising the ATC/DDD L01B antimetabolite and the HTR1A or HTR1B small molecule antagonist is capable of synergistically killing hematological malignancy cells expressing HTR1A or HTR1B.
Dependencies are inferred from the claim text.